- Global Phase 2/3 SPECTRA Trial enrolled over 30,000 adult and elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants
- 100% efficacy against severe COVID-19 and hospitalizations, and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2
- Favorable safety profile; no significant differences in systemic adverse events or severe/serious adverse events compared to placebo
- The impressive results in efficacy and tolerability reflect the beneficial profile of CpG 1018 as a valuable vaccine adjuvant
https://finance.yahoo.com/news/covid-19-vaccine-developed-clover-110500740.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.